Spyre Therapeutics (SYRE) arthritis drug hits target but won’t go forward alone
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. (SYRE) reported topline data from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. In patients with moderate to severely active RA, SPY072 Low Dose achieved a statistically significant improvement in the primary endpoint, change from baseline in DAS28-CRP at Week 12 versus placebo. High and Low Dose arms also showed nominally significant advantages on key secondary and exploratory endpoints, including ACR20 and ACR50 response rates. SPY072 was well tolerated, with overall adverse event rates similar to placebo and no drug-related serious adverse events. The company stated that while the magnitude of effect did not meet its internal threshold to prioritize SPY072 as a monotherapy in RA, the data provide proof-of-mechanism for TL1A and support its potential in other autoimmune diseases and as a combination component. Spyre highlighted upcoming topline readouts across its I&I pipeline through 2027, including SPY003 in ulcerative colitis, additional SPY072 sub-studies in psoriatic arthritis and axial spondyloarthritis, and a combination study of SPY072 with IL-17A/F in hidradenitis suppurativa.
Positive
- SPY072 showed clinically meaningful efficacy signals, with Low Dose improving DAS28-CRP from baseline to Week 12 more than placebo (-1.9 vs -1.3) and higher ACR20/50 response rates in at least one dose arm compared with placebo.
- Favorable safety profile: adverse events occurred in 27% of SPY072-treated patients versus 36% on placebo, were generally mild or moderate, and no serious treatment-emergent adverse events were deemed drug-related.
- Proof-of-mechanism for TL1A in RA and complete suppression of free TL1A through Week 12 support the broader potential of Spyre’s TL1A antibodies in other autoimmune diseases and in combination regimens.
- Multiple near-term catalysts: topline data expected for SPY003 in ulcerative colitis in September 2026, SPY072 in psoriatic arthritis and axial spondyloarthritis in 4Q 2026, and additional SKYLINE and SKYLIGHT readouts through 2027–2028.
Negative
- Effect size below internal bar for RA monotherapy: despite statistical significance on several endpoints, Spyre stated the magnitude of SPY072’s effect did not justify prioritizing its advancement as a standalone RA therapy.
Filing Explained
SPY072 reached complete target engagement through Week 12, but the endpoint results distinguish primary significance from nominal secondary and exploratory findings.
The detailed results qualify the filing’s broad statement that both doses showed statistically significant benefits: statistical significance was reported for the low-dose primary endpoint, while the high-dose ACR20 and low-dose ACR50 findings were labeled nominally significant.
At Week 12, DAS28-CRP changes were -1.5 for high dose, -1.9 for low dose, and -1.3 for placebo; ACR20 responses were
Both doses achieved target drug concentrations and complete, durable suppression of free TL1A through Week 12, which the company said suggested complete target engagement.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ΔDAS28-CRP Week 12 Low Dose: -1.9
ACR20 response rate High Dose: 63%
ACR50 response rate Low Dose: 38%
+4 more
7 metrics
ΔDAS28-CRP Week 12 Low Dose
-1.9
Change from baseline at Week 12 for SPY072 Low Dose versus -1.3 for placebo
ACR20 response rate High Dose
63%
Week 12 ACR20 for SPY072 High Dose versus 43% for placebo
ACR50 response rate Low Dose
38%
Week 12 ACR50 for SPY072 Low Dose versus 19% for placebo
Adverse event rate active vs placebo
27% vs 36%
Overall adverse events in SPY072-treated vs placebo-treated participants
Infections and infestations TEAEs
14% vs 15%
Most common TEAEs in SPY072-treated vs placebo-treated participants
SKYLINE Part A UC topline timing
September 2026
Expected topline data for SPY003 in ulcerative colitis
SKYWAY PsA/axSpA topline timing
4Q 2026
Expected topline data for SPY072 in psoriatic arthritis and axial spondyloarthritis
Key Terms
basket trial, DAS28-CRP, ACR20, Treatment-Emergent Adverse Event, +2 more
6 terms
basket trial medical
"the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases"
A basket trial is a type of clinical study that tests one treatment across multiple diseases or patient groups that share a common biological feature, like a genetic marker. Think of it as trying one key in several different locks that use the same mechanism; positive results can speed development and expand a drug’s potential market, while mixed results can raise uncertainty about which patient groups will benefit and how regulators will view approvals.
DAS28-CRP medical
"The primary endpoint is the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP)"
DAS28-CRP is a standardized score that measures how active rheumatoid arthritis is by counting tender and swollen joints (out of 28) and combining that with a blood inflammation marker called C‑reactive protein. Think of it like a single thermometer reading that summarizes both physical signs and lab evidence of inflammation. Investors watch DAS28-CRP because it is a common clinical trial endpoint and regulatory benchmark used to judge a drug’s effectiveness, which directly affects approval chances and market value.
ACR20 medical
"the secondary endpoint is the proportion of patients achieving an ACR20 response at Week 12"
ACR20 is a clinical-trial measure that indicates a patient has achieved at least a 20% improvement in key symptoms and joint function for inflammatory arthritis, as defined by a standard set of symptom and lab checks. For investors, ACR20 acts like a visible milestone or pass/fail signal: strong ACR20 results suggest a treatment is having a meaningful effect, which can affect regulatory approvals, market expectations and the commercial value of a drug.
Treatment-Emergent Adverse Event medical
"One Serious Treatment-Emergent Adverse Event (“TEAE”) occurred on each arm"
An event is called a treatment-emergent adverse event when a new or worsening unwanted health effect appears after a person starts a drug or medical treatment, typically measured from the first dose onward in clinical studies. Investors watch these events because they can stop or slow product approval, raise development costs, or undermine market confidence—like a widely reported defect in a new gadget that triggers recalls and damages sales.
TL1A medical
"The results provide proof-of-mechanism for TL1A in RA and support its potential"
TL1A is a small signaling protein produced by the immune system that tells certain immune cells to ramp up inflammation, similar to a thermostat that raises the heat in response to a trigger. Investors watch TL1A because drugs or tests that block or measure it can change how inflammatory diseases are treated and diagnosed, affecting the commercial value of therapies, clinical trial outcomes, and potential regulatory approvals.
hidradenitis suppurativa medical
"SKYLIGHT | Hidradenitis Suppurativa (“HS”) | SPY072 + IL-17A/F"
A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.
FAQ
What did Spyre Therapeutics (SYRE) announce about the SPY072 SKYWAY RA sub-study?
Spyre reported topline Phase 2 SKYWAY RA sub-study results showing statistically significant benefits for SPY072 versus placebo on DAS28-CRP and some ACR endpoints, with a well-tolerated safety profile. However, the company said the effect size did not meet its internal bar to prioritize RA monotherapy.
How effective was SPY072 in rheumatoid arthritis in Spyre’s (SYRE) Phase 2 SKYWAY trial?
At Week 12, SPY072 Low Dose improved DAS28-CRP by -1.9 versus -1.3 for placebo. ACR20 responses were 63% (High Dose) and 58% (Low Dose) versus 43% for placebo, and ACR50 responses reached 38% on Low Dose versus 19% on placebo.
What were the safety results for SPY072 in Spyre Therapeutics’ (SYRE) RA sub-study?
SPY072 was well tolerated. Adverse events occurred in 27% of SPY072-treated patients and 36% of placebo patients, were mostly mild or moderate, and serious treatment-emergent adverse events on each arm were not deemed drug-related. One death occurred in a placebo recipient.
Will Spyre Therapeutics (SYRE) advance SPY072 as a monotherapy in rheumatoid arthritis?
Spyre stated that although SPY072 showed statistically significant efficacy and proof-of-mechanism, the magnitude of effect did not meet its internal threshold to prioritize further development of SPY072 as an RA monotherapy, shifting focus to other autoimmune indications and combinations.
What upcoming clinical readouts did Spyre Therapeutics (SYRE) highlight?
Spyre expects topline data for SPY003 in ulcerative colitis (SKYLINE Part A) in September 2026, SPY072 in psoriatic arthritis and axial spondyloarthritis in 4Q 2026, additional SKYLINE Part B ulcerative colitis data in 2027, and SPY072 + IL‑17A/F in HS in late 2027 or early 2028.
What does the SPY072 RA data mean for Spyre Therapeutics’ (SYRE) TL1A platform?
Spyre said the RA data provide proof-of-mechanism for TL1A inhibition, with complete and durable suppression of free TL1A through Week 12, supporting the broad potential of its TL1A antibodies in other autoimmune diseases and as combination components.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2026
_______________________________________________________
(Exact name of Registrant as Specified in Its Charter)
_______________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: | ||
| Not Applicable | ||
(Former Name or Former Address, if Changed Since Last Report)
_______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
(Nasdaq Global Select Market) | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
SPY072 SKYWAY-RA Sub-Study Topline Results
On August 25, 2026, Spyre Therapeutics, Inc. (“Spyre” or the “Company”) issued a press release announcing topline results from the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases.
A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On August 25, 2026, the Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases.
SPY072 SKYWAY-RA Sub-Study Topline Results
The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary endpoint is the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP), and the secondary endpoint is the proportion of patients achieving an ACR20 response at Week 12.
The topline results from the RA sub-study of the Phase 2 SKYWAY basket trial indicated that both SPY072 Low Dose and SPY072 High Dose demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class. The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company’s internal bar to prioritize advancement of SPY072 as a monotherapy in RA.
Efficacy: SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements versus placebo were observed on the secondary endpoint (ACR20) with High Dose and on the exploratory endpoint (ACR50) with Low Dose. Results were generally comparable between advanced-therapy-naïve and advanced-therapy-experienced sub-groups.
| Endpoint (W12) | SPY072 High Dose (N=48) | SPY072 Low Dose (N=48) | Placebo (N=47) | ||||||||
| ΔDAS28-CRP | -1.5 | -1.9* | -1.3 | ||||||||
| ACR20 | 63%** | 58% | 43% | ||||||||
| ACR50 | 31% | 38%** | 19% | ||||||||
| ACR70 | 13% | 4% | 2% | ||||||||
*p<0.05 for SPY072 versus placebo **nominal p<0.05 for SPY072 versus placebo
Both doses of SPY072 achieved target drug concentrations and provided complete and durable suppression of free TL1A through Week 12, suggesting complete target engagement.
Safety: SPY072 was well tolerated, with a safety profile consistent with the TL1A class. Rates of adverse events were comparable between active (27%) and placebo (36%) and generally mild or moderate. One Serious Treatment-Emergent Adverse Event (“TEAE”) occurred on each arm, none deemed drug-related. One death occurred in a participant receiving placebo. The most common TEAEs were infections and infestations, occurring in 14% of SPY072-treated participants and 15% of placebo-treated participants.
Next Steps
The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in immunology and inflammation (“I&I”) with numerous expected topline readouts over the next 12-18 months to prioritize programs for further development:
| Trial | Indication | Asset(s) | Expected timing | ||||||||
| SKYLINE Part A | Ulcerative Colitis (“UC”) | SPY003 | September 2026 | ||||||||
| SKYWAY | Psoriatic Arthritis (“PsA”), Axial Spondyloarthritis (“axSpA”) | SPY072 | 4Q 2026 | ||||||||
| SKYLINE Part B | UC | SPY001, SPY002, SPY003 SPY120, SPY130, SPY230 | 2027 | ||||||||
| SKYLIGHT | Hidradenitis Suppurativa (“HS”) | SPY072 + IL-17A/F | Late 2027 or early 2028 | ||||||||
Forward Looking Statements This Current Report on Form 8-K contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K, other than statements of historical fact are forward-looking statements. These statements include, but are not limited to, statements regarding: the efficacy and safety of SPY072/our TL1A antibodies and their potential in other/a range of autoimmune diseases and as combination components; the Company remaining at the forefront of evaluating potential first and best-in-class monotherapies and combinations in I&I; the expected timing of topline results from the PsA and axSpA SKYWAY sub-studies, SKYLIGHT trial in HS and SKYLINE part A and B in UC and the potential further development of these programs; the timing of and the Company’s ongoing development programs in inflammatory bowel disease and HS; and Spyre’s ongoing and future pre-clinical and clinical development activities. The words “opportunity,” “potential,” “milestones,” “pipeline,” “strategy,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “might,” “plan,” “possible,” “predict,” “should,” “will,” “would,” “can,” “likely,” “aim,” and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and
updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the Securities and Exchange Commission from time to time. You should not place undue reliance on forward-looking statements in this Current Report on Form 8-K, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This Current Report on Form 8-K does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit Number | Description | |||||||
| 99.1 | Press release issued by Spyre Therapeutics, Inc. regarding Data, dated August 25, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPYRE THERAPEUTICS, INC. | |||||||||||
| Date: | August 25, 2026 | By: | /s/ Cameron Turtle | ||||||||
| Cameron Turtle Chief Executive Officer | |||||||||||
Exhibit 99.1
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis
Sub-study of the SKYWAY Phase 2 Trial of SPY072
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)
SPY072 was well tolerated with rates of adverse events comparable to placebo
Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components
Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028
WALTHAM, Mass., August 25, 2026 (GLOBE NEWSWIRE) - Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class. The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company’s internal bar to prioritize advancement of SPY072 in RA.
“The SKYWAY trial was designed to explore the safety and efficacy of TL1A inhibition in a range of rheumatic diseases to identify opportunities for indication-leading products. The results today do not lead us to prioritize SPY072 as a monotherapy in RA. However, the favorable safety profile of TL1A inhibition alongside demonstrated efficacy across inflammatory bowel disease, HS, and now RA provide increased conviction that our long-acting TL1A antibodies have potential in a range of autoimmune diseases and as optimal combination components,” said Cameron Turtle, DPhil, Chief Executive Officer at Spyre. “We want to thank the patients, investigators, and site staff who participated in this study and look forward to results in PsA and axSpA next quarter. Additionally, we are excited to have initiated our SKYLIGHT trial of SPY072 in combination with IL-17A/F in HS, our fourth investigational combination of validated mechanisms in autoimmune indications with high unmet need.”
SKYWAY-RA efficacy results
SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements versus placebo were observed on the secondary endpoint (ACR20) with High Dose and on the exploratory endpoint (ACR50) with Low Dose. Results were generally comparable between advanced-therapy-naïve and advanced-therapy-experienced sub-groups.
| Endpoint (W12) | SPY072 High Dose (N=48) | SPY072 Low Dose (N=48) | Placebo (N=47) | ||||||||
| ΔDAS28-CRP | -1.5 | -1.9* | -1.3 | ||||||||
| ACR20 | 63%** | 58% | 43% | ||||||||
| ACR50 | 31% | 38%** | 19% | ||||||||
| ACR70 | 13% | 4% | 2% | ||||||||
*p<0.05 for SPY072 versus placebo **nominal p<0.05 for SPY072 versus placebo
Both doses of SPY072 achieved target drug concentrations and provided complete and durable suppression of free TL1A through Week 12, suggesting complete target engagement.
Safety results
SPY072 was well tolerated with a safety profile consistent with the TL1A class. Rates of adverse events were comparable between active (27%) and placebo (36%) and generally mild or moderate. One Serious TEAE occurred on each arm, none deemed drug-related. One death occurred in a participant receiving placebo. The most common TEAEs were infections and infestations, occurring in 14% of SPY072-treated participants and 15% of placebo-treated participants.
Next steps
The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in I&I with numerous expected topline readouts over the next 12-18 months to prioritize programs for further development:
| Trial | Indication | Asset(s) | Expected timing | ||||||||
| SKYLINE Part A | Ulcerative Colitis | SPY003 | Sept 2026 | ||||||||
| SKYWAY | PsA, axSpA | SPY072 | 4Q 2026 | ||||||||
| SKYLINE Part B | Ulcerative Colitis | SPY001, SPY002, SPY003 SPY120, SPY130, SPY230 | 2027 | ||||||||
| SKYLIGHT | HS | SPY072 + IL-17A/F | Late 2027 or early 2028 | ||||||||
About SKYWAY-RA
The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial (NCT07148414) and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary endpoint is the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP) and the secondary endpoint is the proportion of patients achieving an ACR20 response at Week 12.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
For more information, visit Spyre's website at www.spyre.com.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding: Spyre’s ability to achieve the expected benefits or opportunities with respect to its product candidates and combinations thereof, including its ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the efficacy and safety of SPY072/ our TL1A antibodies and their broad potential in autoimmune diseases and as optimal combination components; the Company remaining at the forefront of evaluating potential first and best-in-class monotherapies and combinations in I&I; the expected timing of topline results from the PsA and axSpA SKYWAY sub-studies, SKYLIGHT trial in HS and SKYLINE part A and B in UC and the potential further development of these programs; the timing of and the Company’s ongoing development programs in inflammatory bowel disease and HS; and Spyre’s ongoing and future pre-clinical and clinical development activities. The words "opportunity," "potential," "milestones," "pipeline," "strategy," "anticipate," "believe," "could," "estimate," "expect," "may," "might," "plan," "possible," "predict," "should," "will," "would," "can, " "likely," "aim," and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the Securities and Exchange Commission from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com
For Media:
Josie Butler, 1AB
josie@1abmedia.com